TY - JOUR
T1 - Investigation of the Number of Tests Required for Assaying Plasma Biomarkers Associated with Alzheimer’s Disease Using Immunomagnetic Reduction
AU - Liu, Huei Chun
AU - Chen, Hsin Hsien
AU - Ho, Chia Shin
AU - Chang, Jui Feng
AU - Lin, Chia Chun
AU - Chiu, Ming Jang
AU - Chen, Ta Fu
AU - Hu, Chaur Jong
AU - Yan, Sui Hing
AU - Sun, Yu
AU - Yang, Shieh Yueh
N1 - Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - Introduction: Concentrations of plasma biomarkers associated with Alzheimer’s disease have been reported to be as low as several tens of picograms/milliliter (pg/ml). However, in assays measuring these biomarkers, it is likely that repeated measurements are necessary to obtain reliable values. Methods: We performed assays as a single test or as duplicate, quadruplicate, fivefold and tenfold repeated tests, on samples spiked with different concentrations of amyloid β 1–40 (Aβ1–40; 1–1000 pg/ml), Aβ1–42 (1–30,000 pg/ml) and total Tau protein (T-Tau; 0.1–1000 pg/ml), with the aim to to calculate the coefficients of variation (CVs). Results: The results demonstrated common changes in the CVs with changes in the number of tests for a given sample: the CVs decreased with increases in the number of tests from one to ten. All CV values were distributed within the range of 0.35 to 15.5%; as such, the CV values were all lower than the acceptable value of 20%. Conclusion: Based on this study, a single assay of Aβ1–40, Aβ1–42 and T-Tau, respectively, provides reliable results in terms of the measurement of that plasma biomarker.
AB - Introduction: Concentrations of plasma biomarkers associated with Alzheimer’s disease have been reported to be as low as several tens of picograms/milliliter (pg/ml). However, in assays measuring these biomarkers, it is likely that repeated measurements are necessary to obtain reliable values. Methods: We performed assays as a single test or as duplicate, quadruplicate, fivefold and tenfold repeated tests, on samples spiked with different concentrations of amyloid β 1–40 (Aβ1–40; 1–1000 pg/ml), Aβ1–42 (1–30,000 pg/ml) and total Tau protein (T-Tau; 0.1–1000 pg/ml), with the aim to to calculate the coefficients of variation (CVs). Results: The results demonstrated common changes in the CVs with changes in the number of tests for a given sample: the CVs decreased with increases in the number of tests from one to ten. All CV values were distributed within the range of 0.35 to 15.5%; as such, the CV values were all lower than the acceptable value of 20%. Conclusion: Based on this study, a single assay of Aβ1–40, Aβ1–42 and T-Tau, respectively, provides reliable results in terms of the measurement of that plasma biomarker.
KW - Alzheimer’s disease
KW - Immunomagnetic reduction
KW - Plasma biomarkers
UR - http://www.scopus.com/inward/record.url?scp=85114775251&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114775251&partnerID=8YFLogxK
U2 - 10.1007/s40120-021-00280-1
DO - 10.1007/s40120-021-00280-1
M3 - Article
AN - SCOPUS:85114775251
SN - 2193-8253
VL - 10
SP - 1015
EP - 1028
JO - Neurology and Therapy
JF - Neurology and Therapy
IS - 2
ER -